New liquid form of PKU drug tested for equivalence
NCT ID NCT06987773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checks if a new liquid form of sapropterin (RLF-OD032) works the same as the approved powder (Kuvan) in 42 healthy adults. Participants receive a single dose of each version under fed conditions, and blood samples are taken to compare drug levels. The goal is to see if the liquid is a suitable alternative for patients who need this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sapropterin dihydrochloride
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pharma Medica Research Inc. 4770 Sheppard Ave E,
Toronto, Ontario, M1S3V6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.